A chemist based at the University of Copenhagen has just taken out a patent for a drug that can make previously multidrug-resistant bacteria responsive to antibiotics once again.
Jørn Bolstad and his chemist colleagues hope that the substance will soon be able to tackle the tremendous problems associated with multidrug resistant tuberculosis (MDR-TB). But first, they need to find investors interested in getting the substance onto the market.
Before the development of penicillin, people dropped like flies in response to minor infections: in the lungs, in small cuts. Even pimples could grow to boils that killed. But one of the main killers prior to the discovery of antibiotics was tuberculosis.
The deadly infectious disease that typically affects the lungs has returned. It has developed a resistance to the majority of antibiotics that would otherwise kill the tuberculosis bacteria. Currently, the disease does not pose an imminent threat to Denmark or the West. However, resistant strains of the bacteria are nearing the region’s borders. This is one of the reasons why doctors around the world are busy trying to solve the problem of drug resistance.
The bacteria shed killing substances
While those bacteria that have developed a resistance remain vulnerable to antibiotics, they have developed an ability to shed bacteria killing substances before any damage is done to them. Colloquially, this is referred to as pooping the substance out, but the scientific formulation is that these bacteria activate an efflux pump.
Jørn Bolstad Christensen has isolated a substance able to block the efflux pump so that an antibiotic remains in bacteria until the bacteria dies.
You could say that we cure bacteria of their resistance, and slay them with antibiotics, explains Associate Professor Jørn Bolstad Christensen.
From antipsychotic to killing bacteria
Working with doctors Jette Kristiansen from the University of Southern Denmark and Oliver Hendricks from the King Christian X’s Hospital for Rheumatic Diseases in Gråsten, Denmark, Jørn Bolstad Christensen discovered that Thioridazin, an antipsychotic drug, was able to kill bacteria without any noticeably harmful effects upon humans. Still, the chemists had an idea that could make the substance more benign.
We now have a substance that is able to block the bacteria’s efflux pump. At very most, recipients of the medication may become slightly sluggish. This is also because very small doses are needed to affect the bacteria, says Jørn Bolstad Christensen.
Researchers hope for quick approval
Because Thioridazin is an approved drug, the research team hopes that the new anti-resistance medication, JEK 47, will be approved without going through the entire process that new pharmaceuticals are typically subjected to. If this is the case, JEK 47 will most likely be a cheap medication that a pharmaceuticals manufacturer could release quickly. However if an investor does not show interest, Christensen is certain about his next step.
The Latest on: Antibiotic resistance
via Google News
The Latest on: Antibiotic resistance
- Study shows that single water molecule may cause antibiotic resistanceon January 19, 2021 at 9:13 pm
New high-resolution structures of the bacterial ribosome determined by researchers at the University of Illinois Chicago show that a single water molecule may be the cause -; and possible solution -; ...
- Oxford to research antibiotic resistance after receiving £100 million donationon January 19, 2021 at 8:23 pm
Britain's Oxford University has received a donation of £100 million (112 million euros, $136 million) to research growing resistance to antibiotics, the university announced on Tuesday. The sum, from ...
- Unlocking 'the shape of water' in mechanisms of antibiotic resistanceon January 19, 2021 at 5:57 pm
Researchers captured and comparted hi-res images of ribosome structures from sensitive and resistant bacteria and report that a water molecule needed for antibiotic binding was not present in the ...
- Research establishes antibiotic potential for cannabis moleculeon January 19, 2021 at 11:03 am
The main nonpsychoactive component of cannabis has been shown to kill the bacteria responsible for gonorrhoea, meningitis and legionnaires disease, which could lead to the first new class of ...
- £100m awarded to Oxford for research into antibiotic resistanceon January 19, 2021 at 9:33 am
The University of Oxford has been awarded a grant of £100 million pounds to study our growing resistance to antibiotics. The current pandemic has focused minds on the importance of medicine, and the ...
- Oxford University's new mega centre to combat global antibiotic resistanceon January 19, 2021 at 9:13 am
Antimicrobial resistance (AMR) currently causes an estimated 1.5 million excess deaths each year and could cause over 10 million deaths per year by 2050.
- Oxford given £100m for antibiotic resistance researchon January 19, 2021 at 2:54 am
Britain's Oxford University has received a donation of £100 million (112 million euros, $136 million) to research growing resistance to antibiotics, the university announced on Tuesday.
- Oxford research tackles threat of antibiotic resistanceon January 18, 2021 at 6:07 pm
There will be 50 researchers working in the new Ineos Oxford Institute for Antimicrobial Resistance, addressing the "over-use and mis-use" of antibiotics, which the university warned could cause 10 ...
- Researchers show Irish soil can offer more hope in fight against antibiotic resistanceon January 17, 2021 at 2:24 am
Antibiotic resistant superbugs could kill up to 1.3 million people in Europe by 2050—the World Health Organization (WHO) describes the problem as "one of the biggest threats to global health ...
- Researchers provide new insights into how antibiotic resistance developson January 11, 2021 at 10:17 am
Researchers at the Quadram Institute on the Norwich Research Park have shown how the development of antibiotic resistance by bacteria can have 'side-effects' for them including affecting their ability ...
via Bing News